Deep molecular tracking over the 12-yr development of endometrial cancer from hyperplasia in a single patient
Molecular Case Studies · 2023
DOI: 10.1101/mcs.a006311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Case Studies, 2023. Verfasst von Katherine Reid und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; katherine.reid@mssm.edu. Hauptthemen laut MEDLINE: Progesterone, Endometrial Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Although the progressive histologic steps leading to endometrial cancer (EndoCA), the most common female reproductive tract malignancy, from endometrial hyperplasia are well-established, the molecular changes accompanying this malignant transformation in a single patient have never been described. We had the unique opportunity to investigate the paired histologic and molecular features associated with the 12-yr development of EndoCA in a postmenopausal female who could not undergo hysterectomy and instead underwent progesterone treatment. Using a specially designed 58-gene next-generation sequencing panel, we analyzed a total of 10 sequential biopsy samples collected over this time frame. A total of eight pathogenic/likely pathogenic mutations in seven genes, APC , ARID1A , CTNNB1 , CDKN2A , KRAS , PTEN , and TP53 , were identified. A PTEN nonsense mutation p.W111* was present in all samples analyzed except histologically normal endometrium. Apart from this PTEN mutation, the only other recurrent mutation was KRAS G12D, which was present in six biopsy samplings, including histologically normal tissue obtained at the patient's first visit but not detectable in the cancer. The PTEN p.W111* mutant allele fractions were lowest in benign, inactive endometrial glands (0.7%), highest in adenocarcinoma (36.9%), and, notably, were always markedly reduced following progesterone treatment. To our knowledge, this report provides the first molecular characterization of EndoCA development in a single patient. A single PTEN mutation was present throughout the 12 years of cancer development. Importantly, and with potential significance toward medical and nonsurgical management of EndoCA, progesterone treatments were consistently noted to markedly decrease PTEN mutant allele fractions to precancerous levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; katherine.reid@mssm.edu.
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
- Rudy L. Ruggles Biomedical Research Institute, Nuvance Health, Danbury, Connecticut 06810, USA.
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
- Department of Obstetrics/Gynecology and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
Zitieren
APA
Reid, K., Camacho-Vanegas, O., Pandya, D., Camacho, S. C., Qiao, R. F., Kalir, T., Padron-Rhenals, M. M., Beddoe, A. M., Dottino, P., & Martignetti, J. A. (2023). Deep molecular tracking over the 12-yr development of endometrial cancer from hyperplasia in a single patient. Molecular Case Studies. https://doi.org/10.1101/mcs.a006311
Vancouver
Reid K, Camacho-Vanegas O, Pandya D, Camacho SC, Qiao RF, Kalir T, et al. Deep molecular tracking over the 12-yr development of endometrial cancer from hyperplasia in a single patient. Molecular Case Studies. 2023. doi:10.1101/mcs.a006311
BibTeX
@article{Reid2023,
author = {Reid, Katherine and Camacho-Vanegas, Olga and Pandya, Deep and Camacho, Sandra Catalina and Qiao, Rui Fang and Kalir, Tamara and Padron-Rhenals, Maria M and Beddoe, Ann-Marie and Dottino, Peter and Martignetti, John A},
title = {Deep molecular tracking over the 12-yr development of endometrial cancer from hyperplasia in a single patient},
journal = {Molecular Case Studies},
year = {2023},
doi = {10.1101/mcs.a006311}
}
EUVIMED